• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Cardio3 BioSciences will be present at Oddo Midcap Forum

December 17, 2014 By Celyad

Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation in the 18th edition of the ODDO forum, dedicated to European Midcaps, that will take place on 8 and 9 January 2015 in Lyon. The ODDO Midcap forum is renowned as the largest event dedicated to European listed companies.

This event will enable Cardio3 BioSciences to highlight its on-going development programs and strategic vision for the future to potential investors.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “The ODDO Midcap forum is an excellent opportunity to increase Cardio3 Biosciences’ visibility towards European investors, but most importantly it is a unique occasion to present Cardio3 Biosciences’ development potential, positioning and strategic vision.”

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use